Vivos Inc

Vivos Inc. reports Q3 2026 losses, yet boosts liquidity via financing; still focused on Y‑90 RadioGel® and IsoPet® therapy developments.

Vivos Inc. faces volatility on the OTC Bulletin Board—understanding its P/E, market cap, and growth strategies helps investors navigate risks and seize opportunities.

Vivos Inc. on the OTC Bulletin Board: a small-cap’s volatile journey, negative P/E, and strategic challenges in a niche market—investors watch its path to growth.

Vivos Inc. on the OTC Bulletin Board: market cap, price swings, and a negative P/E hint at future growth potential amid volatility.

Vivos Inc. accelerates its yttrium‑90 precision oncology platform, boosting IsoPet® in veterinary oncology and advancing RadioGel® toward FDA approval—while expanding IP, manufacturing, and global reach to sustain growth in the competitive cancer‑tr…

Vivos Inc. shares on the OTC Bulletin Board hit $0.09 in 2026, amid a 52‑week high of $0.1657 and a market cap of $42M, but a negative P/E signals investor challenges.

Vivos Inc. unveils a bold expansion plan to boost global manufacturing and diversify growth, despite current financial challenges and volatile share prices.

Vivos Inc. expands manufacturing globally to boost growth, despite volatile stock and negative earnings; investors watch as expansion could reverse its financial trajectory.

Vivos Inc. faces sharp volatility and negative P/E/B ratios, leaving investors wary despite therapeutic progress—understand the risks before buying.

Vivos Inc.